TScan announced workforce reductions of roughly 30% and confirmed it will stop a Phase I solid tumor T‑cell receptor (TCR) program to concentrate resources on hematologic indications. The reorganisation includes termination of certain development activities and a narrower pipeline focus. Company executives cited the need to preserve capital and prioritise programs with higher near‑term probability of success. The cuts mirror a broader trend among mid‑stage cell therapy companies that are pruning portfolios to extend runways amid investor pressure. Investors and partners will watch TScan’s revised strategy for evidence of clinical traction in blood cancers and for clarity on timelines and funding to support remaining programs.